TickerTalks
Browse all tickers →
TickerTalks›$CELC
CECELC

Celcuity Inc.

Hot onWhy it's trendingX chatter spiked vs its recent normMoving on elevated volume
$CELC·$5.2B·Biotechnology·Healthcare
$88.38+0.1%YTD-11.4%1Y+542.8%
Mentions · last 7 days
2026-07-10: 55 posts2026-07-11: 23 posts2026-07-12: 42 posts2026-07-13: 64 posts2026-07-14: 86 posts2026-07-15: 112 posts2026-07-16: 60 posts448+31%
Price updated 5h ago·X counts updated 1d ago
CECELC
$CELCCelcuity Inc.
$88.38+0.10%448 posts+31%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $CELC, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Driven by hypeSelling offAI verdict · as of 2026-07-16

Falling on heavy selling — points lower unless it turns around.

Celcuity down 18% today on delayed launch after FDA approval — REVTORPYK breast-cancer commercial questions.

Celcuity is a clinical-stage oncology biotech now entering commercial stage — the FDA just approved REVTORPYK (gedatolisib) for HR+/HER2- breast cancer without PIK3CA mutation, and the community's Day-0 label reading is the immediate focus. The stock is down 18% today on delayed launch concerns.

  • Revenue is zero last quarter with -$0.97 EPS — the equity value is entirely a bet on REVTORPYK commercial ramp; the July 14 FDA approval is the pivotal milestone that transitions the company to commercial stage.
  • The delayed breast-cancer drug launch (per news coverage today) is the specific concern driving the -18% move — approval alone doesn't drive revenue if commercial launch timelines slip.
  • The June 3 $400M senior notes offering closed at 0% coupon and the June 8 M&A/growth-company disclosure signal active capital raises around the commercial launch — significant dilution to fund the launch scaling.
  • Zero insider transactions in the last 30 days at 57th percentile of 52-week range — clean absence of distributing signal even into the FDA approval news.
  • Volume multiplier 5.05x — the tape is moving on high volume today, which reflects both the delayed-launch concern and the community's Day-0 label parsing.

August 13 Q2 earnings is where the commercial launch trajectory either gets validated or extends the drawdown: specific FY27 REVTORPYK revenue commentary plus a clear launch-timeline commitment is what restarts the run; continued launch delays or a competitive-labeling issue is where today's -18% extends. Real commercial-stage oncology with real FDA-approval milestone hit — the setup rewards specific launch-execution commentary and is asymmetric event-heavy.

Agrees with X sentimentThe bullish X take on CELC as 'the next real oncology clock' with the RTOR Priority Review timeline and the Day-0 label reading focus is analytically fair. The community's focus on population language and prior-therapy setting is exactly the right question for commercial ramp.

What to watch: Aug 13 Q2 earnings — need specific FY27 REVTORPYK revenue commentary and a clear launch-timeline commitment. Continued launch delays or competitive-labeling issue is where today's -18% extends.

On the calendar: 2026-08-13 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment14 posts analyzed · as of 2026-07-17

Celcuity received first FDA approval for REVTORPYK on July 14 (three days early), with the label covering gedatolisib plus fulvestrant, with or without palbociclib, in HR+/HER2-, PIK3CA wild-type advanced breast cancer. Both doublet and triplet regimens made it onto the label, which posters call a materially better outcome than the base case. The stock nonetheless sold off after approval on a slight launch delay into Q3, and bulls are aggressively buying under $90 ($85-96 add posts), describing the setup as a 'label/indication read' rather than a rejection. Bulls model expansion from 2L to 1L ABC with promising prostate data as a possible path to backbone status in two of the most common cancers. The main critical note is Baker Brothers trimming, which one poster reads as concerning.

Read the AI verdict + X sentiment for $CELC

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage oncology biotech developing molecularly targeted therapies for solid tumors based on cellular pathway analysis.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $CELC.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $CELC

Partial — Clinical-stage oncology biotech developing molecularly targeted therapies for solid tumors based on cellular pathway analysis; the GLP-1 pipeline bifurcation and ADA oral formulation competition is a secondary rather than primary near-term earnings catalyst.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.9%YTD
+44.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-24.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-49.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-4.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-245%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
3.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 14, 2026$-0.97$-1.04+6.7%
Q4 2025Mar 25, 2026$-0.97$-1.06+8.5%
Q3 2025Nov 12, 2025$-0.92$-1.02+9.8%
Q2 2025Aug 14, 2025$-1.04$-0.90-15.6%
Next earningsThu, Aug 13·consensus EPS $-1.08

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.97$-55.3M
Q4 FY25$0———$-0.96$-36.5M
Q3 FY25$0———$-0.92$-44.9M
Q2 FY25$0———$-1.04$-36.3M

Forward consensus

5-year forecast · up to 7 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$42.8M$30.5M – $55.1M-$4.02-$4.24 – -$3.897
FY27$383.0M$226.1M – $540.0M-$0.49-$8.91 – $5.567
FY28$732.1M$723.1M – $741.2M$3.45$0.27 – $6.797
FY29$1.2B$599.0M – $1.9B$7.74$2.81 – $13.553
FY30$1.6B$840.4M – $2.6B$11.22$4.07 – $19.646

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.54%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-19.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-13.2%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 26.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today4.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.165-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 14Baker Bros. Advisors LpFormer 10% owner3.1M sh$317.8MSellMay 4David DalveyDirector25.0K sh$3.5MSellMay 4Richard E BullerDirector9.0K sh$1.3MSellMar 31Richard E BullerDirector3.0K sh$331KSellJan 27David DalveyDirector20.0K sh$2.4M
+ 14 other (7 awards · 4 gifts · 3 exempts) in window

See when $CELC insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13D/AActivist amendmentJul 16SC 13D/A
AI summary

Baker Bros. Advisors LP and related entities (Julian C. Baker, Felix J. Baker, and Baker Bros. Advisors (GP) LLC) filed Amendment No. 2 to their SC 13D on Celcuity Inc. (CELC), disclosing 4,877,963 shares representing 9.99% of the class. Baker Bros. is classified as an investment advisor (IA/PN); no activist intent is stated in the excerpt. Significant position update by a prominent healthcare-focused investment manager at just under the 10% threshold.

8-K/APress release / Reg FD (amended)Jul 158-K/A — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Celcuity (CELC) filed Amendment No. 1 to its 8-K originally dated July 15, 2026, to correct a missing slide in Exhibit 99.2 (investor presentation). The underlying event covered by the original filing was the FDA approval of REVTORPYK (gedatolisib) for the treatment of HR+/HER2- locally advanced or metastatic breast cancer in patients without a PIK3CA mutation who had received at least one prior endocrine therapy. No new substantive information was added beyond the corrected exhibit. This amendment ensures the investor presentation is complete.

8-KPress release / Reg FDJul 158-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Celcuity (CELC) announced on July 14, 2026, that the FDA approved REVTORPYK (gedatolisib) for the treatment of HR+/HER2- locally advanced or metastatic breast cancer in patients without a PIK3CA mutation following at least one prior endocrine-based therapy. The company expects a commercial launch in late Q3 2026 and plans to file a supplemental NDA (sNDA) in Q3 2026 targeting the PIK3CA-mutant breast cancer indication. Gedatolisib is a pan-PI3K/mTOR inhibitor. This approval establishes REVTORPYK in a defined patient population with an unmet need.

8-KAgreement terminatedJun 88-K — Item 1.01: Material agreement · Item 1.02: Agreement terminated · Item 2.03: Material debt obligation · Item 8.01: Other event
AI summary

Celcuity Inc. (CELC) disclosed a material definitive agreement under Item 1.01, reporting a merger or acquisition transaction involving growth company as defined in Rule. The deal is valued at approximately $557.0 million. Details of the transaction terms, consideration structure, and closing conditions are set forth in the full 8-K filing. Definitive merger agreements are among the most material events a public company can disclose, triggering regulatory review and shareholder vote requirements.

424B5Prospectus supplement (offering)Jun 5424B5
AI summary

CELC (CELC) filed a 424B5 prospectus supplement for an offering of senior notes. The offering size is $0 at 0.250 %, due 2032. Proceeds are intended for general corporate purposes, which may include debt repayment, capital expenditures, or working capital. The 424B5 is a prospectus supplement filed under an existing shelf registration, allowing the company to offer securities on an accelerated timeline without a standalone registration statement.

424B5Prospectus supplement (offering)Jun 3424B5
AI summary

CELC (CELC) filed a 424B5 prospectus supplement for an offering of senior notes. The offering size is $400,000,000 at 000 %, due 2032. Proceeds are intended for general corporate purposes, which may include debt repayment, capital expenditures, or working capital. The 424B5 is a prospectus supplement filed under an existing shelf registration, allowing the company to offer securities on an accelerated timeline without a standalone registration statement.

8-KPress release / Reg FDJun 28-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Celcuity announced detailed Phase 3 VIKTORIA-1 trial efficacy and safety results for the PIK3CA mutant-type cohort on June 2, 2026; press release filed as Exhibit 99.1. Potentially pivotal clinical readout — Phase 3 data in a named mutation cohort is a high-impact catalyst for Celcuity's lead oncology program.

8-K/AOfficer or director change (amended)May 208-K/A — Item 5.02: Officer or director change
AI summary

Celcuity Inc. (CELC) filed an 8-K/A (Amendment No. 1) on May 20, 2026 amending a prior February 11, 2026 8-K relating to a personnel change (Item 5.02). Celcuity is a Minneapolis, Minnesota-based clinical-stage oncology company listed on Nasdaq. Amendments to officer/director change disclosures typically correct or supplement compensation arrangement details; this is an administrative filing clarifying terms of an earlier executive change disclosure.

+ 20 other (5 13Gs · 3 8-Ks · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELCprnewswire.com·1d agoCelcuity Inc. (CELC) Discusses FDA Approval of REVTORPYK for Advanced HR+/HER2- Breast Cancer and Commercial Launch Plans Transcriptseekingalpha.com·2d agoCelcuity: 'Buy' REVTORPYK FDA Approval First And sNDA Label Expansion Q3 2026seekingalpha.com·3d agoCelcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approvalreuters.com·3d agoCelcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancermarketbeat.com·3d ago

In themes

Explore the broader themes this ticker is being talked about under.

Best Performers

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$AURA$SLS$RXRX
Voices on X · top 11 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport